As shown in Fig. 1G, they have survival similar to IDHwt TP1 patients, but worse survival than IDHmut-non-codel patients, suggesting that our transcriptomic classification reflects better glioma patient survival prognosis than the IDH-codeletion-based classification. This evidence concerns the gene IDH2 and central nervous system cancer.